Touchlights’s chairman to help lead UK COVID-19 vaccine effort

• Dr. Clive Dix appointed as Deputy Head of the UK’s Vaccine Taskforce

Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this role, Clive will be responsible for building the UK’s vaccine response to Covid-19.

Jonny Ohlson, Touchlight’s founder and CEO, commented: “With over 30 years of experience in life science research, including more than 20 in senior pharma positions, Clive has worked at the forefront of vaccine discovery and development. He has been Chairman of Touchlight for 10 years, providing invaluable guidance into the development of our platform and pipeline, which includes both prophylactic and therapeutic vaccines.

“Clive is a visionary with extraordinary insights into vaccine development. We are convinced that he is the right person to take forward the Covid-19 vaccine initiative in the UK.”

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

For more information please contact: